CRT0273750
CAS No. 1979939-16-6
CRT0273750 ( CRT 0273750; CRT-0273750 )
产品货号. M27971 CAS No. 1979939-16-6
CRT0273750 regulates plasma LPA levels and is suitable for in vivo studies. CRT0273750 is an autotaxin (ATX) inhibitor with IC50 of 0.014 μM.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥640 | 有现货 |
|
5MG | ¥988 | 有现货 |
|
10MG | ¥1596 | 有现货 |
|
25MG | ¥3621 | 有现货 |
|
50MG | ¥5338 | 有现货 |
|
100MG | ¥7606 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称CRT0273750
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述CRT0273750 regulates plasma LPA levels and is suitable for in vivo studies. CRT0273750 is an autotaxin (ATX) inhibitor with IC50 of 0.014 μM.
-
产品描述CRT0273750 regulates plasma LPA levels and is suitable for in vivo studies. CRT0273750 is an autotaxin (ATX) inhibitor with IC50 of 0.014 μM.(In Vitro):CRT0273750 is also shown to inhibit the migration of 4T1 cells with an EC50 of 0.025μM. CRT0273750 shows high potency in both the biochemical (IC50 = 0.01 μM) and plasma choline release assay(IC50 = 0.014 μM).(In Vivo):CRT0273750 treatment shows the Cmax, AUC and t1/2 values of 3.8 μM, 3.2 μM.h and 1.4 h, respectively and shows a proportional increase.CRT0273750 has a moderate blood clearance, with value of 41 mL/min/kg.
-
同义词CRT 0273750; CRT-0273750
-
通路Angiogenesis
-
靶点PDE
-
受体Cannabinoid Receptor
-
研究领域——
-
适应症——
化学信息
-
CAS Number1979939-16-6
-
分子量502.9
-
分子式C25H22ClF3N4O2
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESC[C@H](NC(=O)CCc1nc2cccnc2n1Cc1ccc(OC(F)(F)F)cc1)c1ccc(Cl)cc1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Everett RM, et al. Nephrotoxicity of pravadoline maleate (WIN 48098-6) in dogs: evidence of maleic acid-induced acute tubular necrosis. Fundam Appl Toxicol. 1993 Jul;21(1):59-65.
产品手册
关联产品
-
Mardepodect
A potent and selective PDE10A inhibitor with IC50 of 0.37 nM.
-
RS-25344
RS-25344 is a potent and selective phosphodiesterase (PDE) 4 inhibitor.
-
Triflusal
Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981.